Navigation Links
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results
Date:6/2/2010

ps, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.


'/>"/>
SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... YORK , July 1, 2015  UCB, ... G ), a global leader in designing, transforming, ... Aecus Innovation Award in recognition of their close ... efficiencies in UCB,s global business services (GBS) finance ... service providers and clients that work together effectively ...
(Date:6/30/2015)... WASHINGTON , June 30, 2015  NASA astronaut ... launch next month on his first mission to the ... interviews from 8 to 9 a.m. EDT Tuesday, July 7. ... Center in Star City, Russia . The ... on NASA Television highlighting his mission training. To ...
(Date:6/30/2015)... ... June 30, 2015 , ... Noblis, ... government, announced in a paper published this week in the scientific journal Viruses ... the diagnostic techniques currently used to detect the Ebola virus. Noblis worked with ...
(Date:6/30/2015)... June 30, 2015 /PRNewswire/ - RepliCel Life Sciences ... regenerative medicine company focused on the development of ... in its Phase 1/2 clinical trial of RCT-01, ... Achilles tendinosis, has been enrolled and their tissue ... injections. RCT-01 is comprised of non-bulbar dermal sheath ...
Breaking Biology Technology:UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
...  Echo Therapeutics, Inc. (Nasdaq: ECTE ), a ... wireless, transdermal continuous glucose monitoring (tCGM) system and the ... positive results from its clinical study of its Symphony ... 2 diabetes.  Data from the study confirm that Symphony ...
... been used to create electrical components like resistors, transistors ... But according to Nongjian (NJ) Tao, a researcher at ... inherent in single molecules may also allow clever designers ... performance observed in conventional electronics. In research ...
... NEW YORK, Dec. 5, 2011 Levi & Korsinsky ... the securities of Pacific Biosciences of California, Inc. ("PacBio" ... possible violations of federal securities laws. For ... The investigation stems from allegations that the Company ...
Cached Biology Technology:Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 4S-t-r-e-t-c-h-i-n-g electrical conductance to the limit 2S-t-r-e-t-c-h-i-n-g electrical conductance to the limit 3The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc. 2
(Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... research paper titled "Expanding the Diversity of Mycobacteriophages: Insights ... PLoS ONE , a peer-reviewed online journal published by ... 12 Washington University undergraduates who had participated as freshman ... in St. Louis. Phages are viruses that infect ...
... invertebrates living on the Port Valdez seafloor to stabilize ... scientist at the University of Alaska Fairbanks. "The ... the tsunami waves that followed, impacted every marine community ... assistant professor at the UAF School of Fisheries and ...
... , NEW YORK (April 24, 2011) -- A team ... Surgeons and Weill Cornell Medical College has shed light ... embedded in the cell membranes of neurons that modulate ... The research, published today in the journal ...
Cached Biology News:Phage hunting students publish in PLoS ONE 2Phage hunting students publish in PLoS ONE 3Port Valdez invertebrates stabilized 26 years after quake 2Molecular movements of neural transporters unveiled 2Molecular movements of neural transporters unveiled 3Molecular movements of neural transporters unveiled 4Molecular movements of neural transporters unveiled 5
... Xcell microbial system, 100 to 240 ... electroporation of bacterial and fungal cells. ... PC module for exponential decay delivery, ... (5 each of 0.1 and 0.2 ...
... Epithelial and endothelial cells-directed transfection ... RGD peptide-conjugated polyethylenimine which allows ... epithelial and endothelial cells. Integrins ... cell-cell and cell-matrix adhesion processes. ...
AVOID FREEZE/THAW CYCLES. Recognizes the ~5 kDa thymosin beta4 protein....
... Polymorphic DNA Technologies offers a comprehensive SNP ... for SNP discovery by performing a service ... amplification, DNA sequencing and data analysis. ... Polymorphic uses the gold standard in DNA ...
Biology Products: